Major NIMH Research Project to Test Approaches to Altering the Course of Schizophrenia: Recovery Act Funds Will Support First Phase of Project

The National Institute of Mental Health (NIMH) is launching a large-scale research project to explore whether using early and aggressive treatment, individually targeted and integrating a variety of different therapeutic approaches, will reduce the symptoms and prevent the gradual deterioration of functioning that is characteristic of chronic schizophrenia. The Recovery After an Initial Schizophrenia Episode (RAISE) project is being funded by NIMH with additional support from the American Recovery and Reinvestment Act (ARRA). RAISE is a model example of how money from the Recovery Act can accelerate science related to public health problems and potentially benefit those citizens most in need.
Press Release:

Clinical Research Participation News

NIMH: Bipolar Disorder Genetics: A Collaborative Study

If you have been diagnosed with bipolar disorder (BP) you may be eligible to participate in a research study at the NIH clinical Center. The purpose of this study is to identify genes that may contribute to the development of bipolar disorder (manic depression), and related conditions. Bipolar disorder is a common and potentially life-threatening mood disorder. The tendency to develop bipolar disorder can be inherited, but this is poorly understood and probably involves multiple genes. This study will use genetic markers to map and identify genes that contribute to bipolar disorder. Families and individuals who have the disorder are asked to contribute personal information and a blood sample to an anonymous national database. This information will aid scientists around the world who are working together to develop better treatments for this serious mood disorder.

To find out if you qualify or for more information, please call 1-866-644-4363 or email us at

For more NIMH Clinical Research Information visit here.

FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia

This story appears to have been written by the PR department of the company that makes Invega- the first once-monthly atypicle antipsychotic approved for Schizophrenia in the United States.

Link to full article

Submitted by: Darrell H.